Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine

Recruiting · NCT06335160 · Interventional (participants receive a specific treatment) · Lead sponsor: Tanta University

Interventions studied

Mebendazole

To evaluate the possible efficacy and safety of mebendazole in patients with ulcerative colitis treated with mesalamine

Age range

18 Years to 75 Years

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Not applicable (e.g. observational or device study)

Study type

Interventional (participants receive a specific treatment)

Age ≥ 18 years old Both male and female will be included Mild and moderate UC patients diagnosed and confirmed by endoscope Patient treated with 5-aminosalislic acid (mesalamine)

\- Patients with severe UC
Significant liver and kidney function abnormalities
Diabetic patients
Patients with Colorectal cancer patients
Patients taking rectal or systemic steroids
Patients on immunosuppressants or biological therapies
Addiction to alcohol and / or drugs
Known allergy to the studied medications
History of complete or partial colectomy.
Patients with congestive heart failure, other heart disease (arrhythmia, ischemic heart disease including angina and myocardial infarction).
Patients with other inflammatory diseases and active infection.
Patients with stressful condition (COPD, morbid obesity).
Patients with liver disease.
Patients with thrombocytopenia and neutropenia.
Patients with any type of seizures (case report for mebendazole induced convulsion).
Patients with renal disease (case report for mebendazole induced nephrotoxicity).
Patients with coagulation disorders.
Patients on metronidazole (to avoid Stevens-Johnson syndrome).
Patients with hypersensitivity to mebendazole, albendazole or benzimidazole
Patients using antioxidants.
Pregnant and lactating females.
Patients receiving, metronidazole, warfarin, low dose of aspirin, clopidogril, enzyme inducers (phenytoin, carbamazepine) and inhibitors (valoproate) to avoid potential pharmacodynamics and pharmacokinetic interactions.

1 location listed.